Impact of the end of public health emergency oral dispensing flexibilities for at-risk patients in a community oncology practice.

Authors

Lalan S. Wilfong

Lalan S. Wilfong

Texas Oncology, The US Oncology Network, Dallas, TX

Lalan S. Wilfong, Neal Dave, Wendy Hemmen, Erica Feinberg, Gury K. Doshi

Organizations

Texas Oncology, The US Oncology Network, Dallas, TX, Texas Oncology, Dallas, TX, US Oncology Network, Dallas, TX, Texas Oncology PA, Houston, TX

Research Funding

No funding received
None.

Background: Many studies have shown the benefit of medically integrated pharmacies for cancer specialty oral drugs in improving patient adherence and reducing waste compared to external pharmacies. Anti-kickback regulations have limited practice’s ability to deliver prescriptions to patient’s homes from physician offices. During the Covid Public Health Emergency (PHE), flexibility for prescription delivery by a physician owned pharmacy was allowed leading many practices to deliver oral cancer therapies to patients who could not otherwise come to clinics to fill their medications. With the end of the PHE, CMS reversed this flexibility. We sought to determine the impact on patients with this change in CMS regulations. Methods: Utilizing the pharmacy database of prescriptions delivered to a patient’s home for a large statewide community oncology practice in Texas during the PHE, we identified patients with Medicare part D who would no longer be able to utilize their physician’s pharmacy for home delivery of their specialty medications. We determined the distance of those patient’s primary address to the nearest clinic and further matched them to the address deprivation index (ADI) a well-validated approach that rank orders zip codes in deciles from lowest to highest need. Results: We found 970 patients receiving home delivered prescriptions with traditional Medicare Part D. 687 or 71% of patients lived within 20 miles of the nearest clinic. 213 or 22% lived between 20 and 50 miles with 70 or 7% more than 50 miles from the nearest clinic. 60 addresses could not be matched to the ADI database. Focusing on those available addresses in the top half of the ADI at highest need, we found that 40% of patients living within 20 miles of the clinic are at significant risk of disparity vs 67% of those 20-50 miles and 61 % of those living more than 50 miles from the clinic. Conclusions: The removal of the PHE flexibility for home delivery of prescriptions from physician offices will significantly increase the burden on patients in Texas, forcing many to drive long distances to obtain drugs and disproportionately affecting those at greatest risk of disparity. We encourage revising policies to allow medically integrated pharmacies to allow home delivery of cancer specialty drugs to meet CMS stated goals of improving health equity.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care

Sub Track

Interventions and Policies to Optimize Health Equity

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 209)

DOI

10.1200/OP.2023.19.11_suppl.209

Abstract #

209

Poster Bd #

F20

Abstract Disclosures

Similar Abstracts

First Author: Marina D. Kaymakcalan

Abstract

2023 ASCO Quality Care Symposium

Impact of medically integrated pharmacies on oral anticancer medication prescription abandonment.

First Author: Gury K. Doshi

First Author: Alan H. Breaud